Clinical Trial Search

Primary: Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30 — -1.13; -0.62 percentage of HbA1c — p=<0.0001

Primary: Change in the Density of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Following Antiretroviral Therapy Regimen — 24; 89; 119; 566…

Primary: Change Number of Standard Drinks Per Week. — -26.2; -25.5 standard drinks per week — p=0.9

Primary: 30-day Hospital Readmission — 11; 9 30-day hospital readmissions

Primary: Quality of Motor Performance — .49; .67 percentage of samples not 'on' task

Primary: Change in Thickness of Buccal Bone — .73; .86; .63; .66 millimeters

Primary: Number of Dose Limiting Toxicities for Determining Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With 5-azacytidine (5-AZA) — 0; 0; 0; 0 participants

Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24

Primary: Self-reported 30-day Point Prevalence Abstinence — 166; 146; 182; 184 Participants

Primary: The Percentage of Participants Who Exhibit a Hematopoietic Response — 68.9; 61.7; 65.5; 66.7 Percentage of participants — p=>0.41

Primary: Change Over 6 Months in Epworth Sleepiness Scale Score — -0.23; -1.05; 0.43; -2.62 units on a scale

Primary: Plasma Viral Load Suppression — 26; 23; 23; 24 participants

Primary: The Tolerability of BuMel Regimen — 9 participants

Primary: The Percentage of Participants With Asthma Who Rated the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrated Correct Use of the Inhaler at the…

Primary: Event Free Survival Without Receiving Radiation Therapy (EFSnoRT). — 0.49 Probability of survival